Key facts
- It has raised $760K across 1 recorded rounds; the latest was Accelerator/Incubator in Mar 2024.
- Notable investors include Springboard Enterprises, Nashville Entrepreneur Center, Fulcrum Ventures, INSPYRE.
- Ursamin has filed 1 Form D with the SEC, most recently Jun 2025 ($55K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ursamin
Funding rounds
1 roundsAbout Ursamin
Developer of a healthcare software platform designed to provide easy access to medical records and targeted education to patients and healthcare givers. The company's platform offers to help patients collect all medical information for themselves and their extended families, by consolidating the patient's engagement with the healthcare ecosystem into one view and layering in features that meet each user's needs, enabling providers, patients and caregivers to partner together in the management of a patient's chronic illness through collaboration and communication tools.
- Industry
- Information Services (B2C)
- Sector
- Consumer Products and Services (B2C)
- HQ
- Fayetteville, NY, United States
- Founded
- 2020
- Employees
- 6
- Website
- ursamin.com/
- Ownership
- Privately Held (backing)
Ursamin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ursamin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ursamin in its N-PORT filings yet. We sweep new filings monthly.